Friday, October 2, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 10, 2026

Einride to Appoint Former NVIDIA Executive Gary Hicok to Board of Directors

View original at finance.yahoo.com
Einride to Appoint Former NVIDIA Executive Gary Hicok to Board of Directors STOCKHOLM, Feb…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Einride is solving an industry-scale problem the right way. Its platform approach unlocks partnerships, accelerates innovation, and makes electrified and autonomous freight real.

    80% confidence

  • Many smart companies struggle with doing everything in house. It doesn't scale or leverage the expertise of the industry, whereas Einride's approach does.

    80% confidence

  • Gary's expertise and experience in building high-performing teams tackling the most advanced technology development will be instrumental for Einride as it continues to scale and cement its leadership position within autonomous freight technology.

    80% confidence

  • Completion of the Transaction with Legato is anticipated to occur in the first half of 2026 subject to customary closing conditions, including regulatory approvals.

    80% confidence

  • Gary brings deep, hands-on experience scaling autonomous technology through critical partnerships across the automotive and technological ecosystem. His perspective on building and scaling safety-critical platforms with industry partners will strengthen Einride's ability to deploy autonomy globally.

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com